Atopic Dermatitis ' Pipeline Review, H1 2013

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Atopic Dermatitis ' Pipeline Review, H1 2013
Published on February 2013

Report Summary


Summary

Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for Atopic Dermatitis, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atopic
Dermatitis. Atopic Dermatitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's
proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Atopic Dermatitis.
- A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Atopic Dermatitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Atopic Dermatitis ' Pipeline Review, H1 2013 (From Slideshare) Page 1/9


Table of Content

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Atopic Dermatitis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Atopic Dermatitis 11
Atopic Dermatitis Therapeutics under Development by Companies 13
Atopic Dermatitis Therapeutics under Investigation by Universities/Institutes 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Discovery and Pre-Clinical Stage Products 22
Atopic Dermatitis Therapeutics ' Products under Development by Companies 23
Atopic Dermatitis Therapeutics ' Products under Investigation by Universities/Institutes 28
Companies Involved in Atopic Dermatitis Therapeutics Development 29
Bristol-Myers Squibb Company 29
Amgen Inc. 30
GlaxoSmithKline plc 31
Daiichi Sankyo Company, Ltd 32
Merck & Co., Inc. 33
Taisho Pharmaceutical Co., Ltd. 34
Novartis AG 35
Chugai Pharmaceutical Co. Ltd 36
Eisai Co., Ltd. 37
Galderma S.A. 38
LEO Pharma A/S 39
Nippon Shinyaku Co., Ltd. 40
Sandoz Inc. 41
Bayer AG 42
AlbireoPharma 43
Almirall, S.A. 44
NicOx SA 45
Regeneron Pharmaceuticals, Inc. 46
Array BioPharma Inc. 47
ProMetic Life Sciences Inc. 48
Phytopharm Plc 49
Hanall Pharmaceutical Co., Ltd. 50
AnGes MG, Inc. 51



Provectus Pharmaceuticals, Inc. 52
Proximagen Neuroscience plc. 53
R-Tech Ueno, Ltd. 54
Paloma Pharmaceuticals, Inc. 55
Asubio Pharmaceuticals, Inc. 56
SCYNEXIS, Inc. 57
Palau Pharma S.A 58
Foamix Ltd. 59
Respiratorius AB 60
MIKA Pharma GmbH 61
CREABILIS Therapeutics S.r.l. 62
Anacor Pharmaceuticals, Inc. 63
JADO Technologies GmbH. 64
IMMD Inc. 65
Circassia Holdings Ltd. 66
Hawthorn Pharmaceuticals, Inc. 67
Amalyte Pharmaceuticals, LLC 68
Astion Pharma A/S 69
Melior Discovery, Inc. 70
Welichem Biotech Inc. 71
Cutanea Life Sciences 72
Action Pharma A/S 73
SWITCH Biotech LLC 74
Lytix Biopharma AS 75
Maruho Co.,Ltd. 76
Pharis Biotec GmbH 77
Viromed Co., Ltd. 78
Immune Technologies and Medicine 79
Clarassance, Inc. 80
Atopic Dermatitis ' Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Route of Administration 82
Assessment by Molecule Type 84
Drug Profiles 86
GW-870086X - Drug Profile 86
BMS-981164 - Drug Profile 88
SB-705498 - Drug Profile 89
MK-52 - Drug Profile 91
tarenflurbil - Drug Profile 93
SUN-13834 - Drug Profile 94
NCX-1047 - Drug Profile 95
AMG-157 - Drug Profile 96
CT-327 - Drug Profile 97
omiganan pentahydrochloride - Drug Profile 99
PH-10 - Drug Profile 101
DPK-060 - Drug Profile 103
cobamamide - Drug Profile 104



LEO-29102 - Drug Profile 105
Topical PDE-4 Inhibitors - Drug Profile 106
PYM-60001 - Drug Profile 107
DNK-333 - Drug Profile 108
IMD-0354 - Drug Profile 109
WBI-1001 - Drug Profile 110
PBI-1308 - Drug Profile 112
ProtoCure Emulsion Cream - Drug Profile 113
AN-2898 - Drug Profile 115
LAS-41004 - Drug Profile 116
J-607Y - Drug Profile 117
NFkappaB Decoy Oligodeoxynucleotide - Drug Profile 119
NFkappaB Decoy Oligodeoxynucleotide - Drug Profile 121
mapracorat - Drug Profile 123
AP-405 - Drug Profile 126
AN-2728 - Drug Profile 127
NS-141 - Drug Profile 129
SWT-01113 - Drug Profile 130
SWT-05141 - Drug Profile 131
PAR-2 Program - Drug Profile 132
RTU-1096 - Drug Profile 133
P-529 - Drug Profile 134
LTX-109 - Drug Profile 136
anakinra - Drug Profile 138
dupilumab - Drug Profile 139
PAP-1 - Drug Profile 141
E-6005 - Drug Profile 142
Haw S-13 - Drug Profile 143
M-516102 - Drug Profile 144
Product-0405 - Drug Profile 145
UR-65318 - Drug Profile 146
PG-102 - Drug Profile 147
LEKTI-6 - Drug Profile 148
REGN-846 - Drug Profile 149
M-5200 - Drug Profile 151
MLR-1130 - Drug Profile 152
A-3914 - Drug Profile 153
RESP-1200 - Drug Profile 154
SIG-1311 - Drug Profile 155
QGE-031 - Drug Profile 156
RS-1269 - Drug Profile 158
CD-4802 - Drug Profile 159
RESP-5000 - Drug Profile 160
DS-107 - Drug Profile 161
SB-011 - Drug Profile 162



CG-690 - Drug Profile 165
XGP-510 - Drug Profile 166
ASB-17061 - Drug Profile 167
PL-601 - Drug Profile 168
BBI-2111 - Drug Profile 169
Cyclophilin Inhibitory Compounds - Drug Profile 170
ARRY-005 - Drug Profile 171
CIM-331 - Drug Profile 172
Urocanic Acid Derivatives - Drug Profile 173
GD-48 - Drug Profile 174
HS-378 - Drug Profile 175
A-5425 - Drug Profile 176
betamethasone - Drug Profile 177
CDE-001 - Drug Profile 178
TKM-0150 - Drug Profile 179
Atopic Dermatitis Therapeutics ' Drug Profile Updates 180
Atopic Dermatitis Therapeutics ' Discontinued Products 194
Atopic Dermatitis Therapeutics - Dormant Products 195
Appendix 199
Methodology 199
Coverage 199
Secondary Research 199
Primary Research 199
Expert Panel Validation 199
Contact Us 200
Disclaimer 200

List of Tables

Number of Products Under Development for Atopic Dermatitis, H1 2013 16
Products under Development for Atopic Dermatitis ' Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Comparative Analysis by Mid Clinical Stage Development, H1 2013 25
Comparative Analysis by Early Clinical Stage Development, H1 2013 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Development by Companies, H1 2013 (Contd..1) 29
Products under Investigation by Universities/Institutes, H1 2013 33



Bristol-Myers Squibb Company, H1 2013 34
Amgen Inc., H1 2013 35
GlaxoSmithKline plc, H1 2013 36
Daiichi Sankyo Company, Ltd, H1 2013 37
Merck & Co., Inc., H1 2013 38
Taisho Pharmaceutical Co., Ltd., H1 2013 39
Novartis AG, H1 2013 40
Chugai Pharmaceutical Co. Ltd, H1 2013 41
Eisai Co., Ltd., H1 2013 42
Galderma S.A., H1 2013 43
LEO Pharma A/S, H1 2013 44
Nippon Shinyaku Co., Ltd., H1 2013 45
Sandoz Inc., H1 2013 46
Bayer AG, H1 2013 47
AlbireoPharma, H1 2013 48
Almirall, S.A., H1 2013 49
NicOx SA, H1 2013 50
Regeneron Pharmaceuticals, Inc., H1 2013 51
Array BioPharma Inc., H1 2013 52
ProMetic Life Sciences Inc., H1 2013 53
Phytopharm Plc, H1 2013 54
Hanall Pharmaceutical Co., Ltd., H1 2013 55
AnGes MG, Inc., H1 2013 56
Provectus Pharmaceuticals, Inc., H1 2013 57
Proximagen Neuroscience plc., H1 2013 58
R-Tech Ueno, Ltd., H1 2013 59
Paloma Pharmaceuticals, Inc., H1 2013 60
Asubio Pharmaceuticals, Inc., H1 2013 61
SCYNEXIS, Inc., H1 2013 62
Palau Pharma S.A, H1 2013 63
Foamix Ltd., H1 2013 64
Respiratorius AB, H1 2013 65
MIKA Pharma GmbH, H1 2013 66
CREABILIS Therapeutics S.r.l., H1 2013 67
Anacor Pharmaceuticals, Inc., H1 2013 68
JADO Technologies GmbH., H1 2013 69
IMMD Inc., H1 2013 70
Circassia Holdings Ltd., H1 2013 71
Hawthorn Pharmaceuticals, Inc., H1 2013 72
Amalyte Pharmaceuticals, LLC, H1 2013 73
Astion Pharma A/S, H1 2013 74
Melior Discovery, Inc., H1 2013 75
Welichem Biotech Inc., H1 2013 76
Cutanea Life Sciences, H1 2013 77
Action Pharma A/S, H1 2013 78
SWITCH Biotech LLC, H1 2013 79
Lytix Biopharma AS, H1 2013 80
Maruho Co.,Ltd., H1 2013 81



Pharis Biotec GmbH, H1 2013 82
Viromed Co., Ltd., H1 2013 83
Immune Technologies and Medicine, H1 2013 84
Clarassance, Inc., H1 2013 85
Assessment by Monotherapy Products, H1 2013 86
Assessment by Stage and Route of Administration, H1 2013 88
Assessment by Stage and Molecule Type, H1 2013 90
Atopic Dermatitis Therapeutics ' Drug Profile Updates 185
Atopic Dermatitis Therapeutics ' Discontinued Products 199
Atopic Dermatitis Therapeutics ' Dormant Products 200
Atopic Dermatitis Therapeutics ' Dormant Products (Contd..1) 201

List of Figures

Number of Products under Development for Atopic Dermatitis, H1 2013 16
Products under Development for Atopic Dermatitis ' Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 24
Mid Clinical Stage Products, H1 2013 25
Early Clinical Stage Products, H1 2013 26
Discovery and Pre-Clinical Stage Products, H1 2013 27
Assessment by Monotherapy Products, H1 2013 86
Assessment by Route of Administration, H1 2013 87
Assessment by Stage and Route of Administration, H1 2013 88
Assessment by Molecule Type, H1 2013 89
Assessment by Stage and Molecule Type, H1 2013 90


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Atopic Dermatitis ' Pipeline Review, H1 2013

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Atopic Dermatitis ' Pipeline Review, H1 2013